Leqvio (inclisiran sodium) Drug Profile in 2024
Leqvio, with the active ingredient inclisiran sodium, is a medication used to lower cholesterol levels. It targets the PCSK9 protein, playing a key role in managing cardiovascular disease risk.
How does Leqvio work to lower cholesterol?
Leqvio functions by inhibiting the synthesis of the PCSK9 protein in the liver. PCSK9 normally binds to LDL receptors on liver cells, leading to their degradation. By reducing PCSK9 levels, Leqvio increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream, thus lowering "bad" cholesterol [1].
What is the typical dosing schedule for Leqvio?
The recommended dosage for Leqvio involves an initial dose, a follow-up dose at three months, and then a maintenance dose every six months thereafter [1]. This infrequent dosing schedule is a distinguishing feature of the medication.
How effective is Leqvio in reducing LDL cholesterol?
Clinical trials have demonstrated significant reductions in LDL cholesterol with Leqvio. Studies have shown an average LDL cholesterol reduction of over 50% at 17 months after the initial dose, with sustained effects seen with continued dosing [1].
When does Leqvio's patent protection expire?
Information regarding Leqvio's patent expiration is subject to ongoing developments and potential legal challenges. DrugPatentWatch.com tracks patent statuses for medications like Leqvio, providing details on granted patents, expiration dates, and any related litigation that could affect market exclusivity [2]. Generally, understanding patent timelines is crucial for predicting the potential introduction of generic or biosimilar alternatives.
What are the potential side effects of Leqvio?
Common side effects associated with Leqvio include injection site reactions, such as pain, redness, or itching. Other reported side effects can include influenza, cold symptoms, and diarrhea [1]. Serious allergic reactions are rare but possible [1].
Who manufactures Leqvio?
Leqvio is developed and marketed by Novartis [1].
How does Leqvio compare to other cholesterol-lowering medications?
Leqvio offers a distinct advantage with its infrequent dosing compared to daily oral statins or other oral cholesterol medications. Unlike statins that work by reducing cholesterol production, Leqvio directly targets PCSK9 to enhance LDL receptor activity. This makes it a valuable option for patients who are unable to reach their LDL cholesterol goals with maximally tolerated statin therapy or who have other contraindications to statins [1].
What is the clinical data supporting Leqvio's use?
The efficacy and safety of Leqvio have been established in several large-scale clinical trials, including the ORION-9, -10, and -11 studies. These trials involved diverse patient populations with various levels of cardiovascular risk and hypercholesterolemia, consistently showing substantial LDL-C reduction and a favorable safety profile [1].
What are the regulatory approvals for Leqvio?
Leqvio has received approval from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C [1].
What are the patient concerns regarding Leqvio?
Patients may have questions about the administration of Leqvio, as it is an injectable medication. Understanding the infrequent dosing schedule can be a significant benefit. Concerns may also arise regarding potential side effects and how Leqvio fits into their overall treatment plan for managing cholesterol and cardiovascular risk [1].
---
Sources:
[1] Leqvio Prescribing Information.
[2] DrugPatentWatch.com